Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalised for chest pain and potential acute coronary syndrome.~* Onset of the most recent cardiac ischemic symptoms must occur within 7 days before randomisation and documented by cardiac ischemic symptoms of ≥ 10 min duration at rest and at least 2 of the following: ST segment changes on electrocardiogram (ECG) indicative of ischemia, or Positive biomarker evdience of myocardial necrosis, or other risk factors such as: 60 yrs of age or older, previous myocardial infarction or coronary bypass surgery, multi-vessel coronary artery disease, diabetes mellitus, peripheral arterial disease, chronic renal disfunction.~* Females must be either surgically sterile or post-menopausal.~* Activated Clotting Time (ACT) \</= 300 at the time of study treatment~Exclusion Criteria:~* Participation in another clinical study with an investigational product during the last 30 days.~* Current acute complication of percutaneous coronary intervention or coronary bypass surgery.~* Any contraindication to ticagrelor, clopidogrel or bivalirudin.~* ST elevation myocardial infraction within 24 hours of study entry.~* Any indications for oral anticoagulation or aspirin dose other than 75 to 100 milligrams (mg) daily.~* Planned use of omeprazole or esomeprazole.~* Patients with known bleeding or coagulation disorders; patients requiring dialysis; patients who have an inability to swallow medication.~* Patients with known bleeding diathesis or coagulation disorder; history of intracranial bleed.~* Use of Intravenous (IV) heparin less than 2 hours before procedure.~* Sustained uncontrolled high blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): 90 mg oral tablet
- Clopidogrel (Type: ACTIVE_COMPARATOR): 300 mg oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).